Comparative Pharmacology
Head-to-head clinical analysis: METAXALONE versus RYANODEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METAXALONE versus RYANODEX.
METAXALONE vs RYANODEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metaxalone is a centrally acting muscle relaxant whose exact mechanism is unknown. It is thought to produce skeletal muscle relaxation by depressing the central nervous system (CNS), possibly through general CNS depression or by blocking polysynaptic reflexes in the spinal cord.
Ryanodine receptor agonist; stabilizes the ryanodine receptor (RyR1) channel in skeletal muscle, reducing calcium leakage and improving excitation-contraction coupling.
800 mg orally 3 to 4 times daily
Dantrolene sodium: 2.5 mg/kg IV bolus, repeated as needed up to a cumulative dose of 10 mg/kg, then 1 mg/kg IV every 6 hours for 24-48 hours following malignant hyperthermia crisis.
None Documented
None Documented
Clinical Note
moderateMetaxalone + Venlafaxine
"The risk or severity of adverse effects can be increased when Metaxalone is combined with Venlafaxine."
Clinical Note
moderateMetaxalone + Nefazodone
"The risk or severity of adverse effects can be increased when Metaxalone is combined with Nefazodone."
Clinical Note
moderateMetaxalone + Stiripentol
"The risk or severity of adverse effects can be increased when Metaxalone is combined with Stiripentol."
Clinical Note
moderateMetaxalone + Clomipramine
Terminal elimination half-life is approximately 0.5 to 1.5 hours, reflecting rapid clearance and supporting short-lived clinical effects.
Terminal elimination half-life is approximately 1.5-2 hours in healthy adults; prolonged in patients with hepatic impairment.
Primarily renal; approximately 90% of a dose is excreted in urine as glucuronide conjugates and unchanged drug, with less than 1% eliminated in feces via biliary excretion.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal excretion of metabolites accounts for the majority of elimination.
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
"The risk or severity of adverse effects can be increased when Metaxalone is combined with Clomipramine."